This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
XTALKS WEBINAR: Environmental Sustainability and the Supply of Medicines for ClinicalTrials Live and On-Demand: Thursday, January 16, 2025, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how major pharmacompanies are working towards environmental sustainability and reducing their environmental impact.
So, how can pharmacompanies use content marketing to engage HCPs and patients effectively ? Pharma brands can develop: Whitepapers on clinicaltrials showcasing drug effectiveness. Scientific blogs discussing new advancements in oncology, cardiology, or rare diseases. Lets dive in.
We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.
The heart and vascular medication market continues to be a critical focus area for pharmacompanies, with billions of dollars in sales generated annually. Their widespread adoption is driven by strong clinical evidence, broad FDA-approved indications and continued advancements in treatment protocols.
The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinicaltrial results. Currently, no such cholesterol/blood pressure polypill exists in the United States, Yusuf said.
By leveraging digital tools, content personalization, and interactive experiences, pharmacompanies can enhance engagement and build long-term relationships. This article explores effective audience engagement strategies tailored for pharma marketers, focusing on both HCPs and patients.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content